Investors give up on diabetes drug maker DiObex
After failing to raise a sustaining round of capital, DiObex has been effectively shut down by its investors. They have laid off the San Francisco company’s eight employees and are moving to quickly sell off its assets, including its lead drug candidate, a compound that prevents hypoglycemia in diabetes patients.
DiObex originally launched with $30 million from Domain Associates, Inventages Venture Capital, Pequot Capital, Sofinnova Ventures and several others in 2003. In the past year or so, it has been looking for an additional $20 to $30 million to push its drug through a second phase of clinical trials. But all potential investments would have caused a steep decline in the company’s valuation. Its existing backers decided it would be more lucrative to simply sell the rights to the drug, called DIO-901.
So far there have been no takers, and it’s unclear whether the investors will in fact get a return from the sale, according to VentureWire. While it had another type 2 diabetes treatment in development, it had stopped working on it due to safety concerns. The Food and Drug Administration has sharpened its teeth when it comes to approving diabetes medications of late due to past safety problems.
Next Story: Tiseme brings Facebook-style feeds to the rest of the web
Previous Story: Cisco buys Tidal Software for $105M — to virtualize the data center
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.